The world's most expensive prescription drug, Glybera , has been discontinued due to lack of demand. the MIT Center for Biomedical Innovation contains engineered viruses carrying copies of a gene to treat a rare metabolic disease, lipoprotein lipase deficiency, and costs $1 million for a one -time set of injections. But low demand for the therapy and questions about its effectiveness have plagued Glybera’s manufacturer, UniQure, based in Amsterdam and Lexington, Massachusetts. Its approval by European drug regulators in October was seen as a milestone for gene therapy after a number of setbacks and safety issues. But its usage has been "extremely limited", according to manufacturer UniQure , which will not renew the drug's European marketing authorisation when it expires in October .
The world's most expensive prescription drug, Glybera , has been discontinued due to lack of demand. the MIT Center for Biomedical Innovation contains engineered viruses carrying copies of a gene to treat a rare metabolic disease, lipoprotein lipase deficiency, and costs $1 million for a one -time set of injections. Its approval by European drug regulators in October was seen as a milestone for gene therapy after a number of setbacks and safety issues. But its usage has been "extremely limited", according to manufacturer UniQure , which will not renew the drug's European marketing authorisation when it expires in October .